UK study finds vaccines offer high protection against hospitalisation from Delta variant

London (Reuters) – COVID-19 vaccines made by Pfizer and AstraZeneca offer high protection of more than 90% against hospitalisation from the Delta coronavirus variant, a new analysis by Public Health England (PHE) showed on Monday.

Prime Minister Boris Johnson is expected to announce a delay to the lifting of COVID-19 restrictions in England due to the spread of the highly transmissible Delta variant of concern, first identified in India, which is also associated with a higher risk of hospitalisation among the unvaccinated.

PHE said that the Pfizer/Biontech COVID-19 vaccine was 96% effective against hospitalisation from the Delta variant after two doses, while Oxford/AstraZeneca’s offered 92% protection against hospitalisation by Delta.

PHE said that those levels of protection were comparable to that against the Alpha variant, first identified in Kent, southeast England.

The analysis adds to evidence that, although the Delta variant reduces the effectiveness of vaccines against symptomatic infection, two doses of COVID-19 vaccine still protect against severe disease.

“These hugely important findings confirm that the vaccines offer significant protection against hospitalisation from the Delta variant,” said Mary Ramsay, Head of Immunisation at PHE.

The PHE findings follow a Scottish study which showed that two doses of a COVID-19 vaccine among people who tested positive cut their risk of hospitalisation by 70%, although there were not enough hospital admissions reported to compare the vaccines.

PHE said that while further work was being undertaken to establish the level of protection against mortality from the Delta variant, levels of protection against death were expected to be high.